Piper says Amag goal to add 174 patients to trial by 2019 ‘may be a tall order’

Piper Jaffray analyst Christopher Raymond noted that Amag Pharmaceuticals announced it has taken over development of digoxin immune Fab for the treatment of severe preeclampsia from Velo Bio and seeks to add an additional 174 patients by the end of 2019, which he believes “may be a tall order.” As he waits to see how enrollment progresses for this trial, he continues to have concerns with Amag’s current franchise as Makena, which makes up over 70% of revenue, recently began facing generic competition, Raymond tells investors. The analyst maintains a Neutral rating on Amag shares and says he is still “comfortable on the sidelines.”

https://thefly.com/landingPageNews.php?id=2795955